

U.S.S.N.: 10/743,892

Filed: December 22, 2003

AMENDMENT AND RESPONSE TO OFFICE ACTION

In the Claims

1-14. (canceled)

15. (currently amended) A method for promoting wound healing in a subject, comprising administering to a subject a therapeutically effective amount of a composition comprising an osteopontin derived chemotactic peptide, wherein the peptide is not full-length osteopontin, and a pharmaceutically-acceptable carrier or diluent such that wound healing is promoted.

16-17. (canceled)

18. (previously presented) The method of claim 15, wherein the therapeutic composition is administered topically.

19-20. (canceled)

21. (withdrawn-currently amended) A method for promoting cell migration to a target site in a subject comprising administering at the target site in the subject a therapeutically effective amount of an osteopontin derived chemotactic peptide, wherein the peptide is not full-length osteopontin, for a time and under conditions such that migration of the cell to the target site is promoted, wherein the cell bears receptors that recognize a peptide in the therapeutic composition.

22. (withdrawn-currently amended) A method for inducing *in vitro* cellular chemotaxis, comprising incubating a cell in the presence of a therapeutically effective amount of an osteopontin derived chemotactic peptide, wherein the peptide is not full-length osteopontin, for a time and under conditions effective to induce chemotaxis of the cell, wherein the cell bears receptors that recognize the peptide.

23-25. (canceled)

U.S.S.N.: 10/743,892

Filed: December 22, 2003

AMENDMENT AND RESPONSE TO OFFICE ACTION

26. (withdrawn-currently amended) A method for inhibiting the formation of atherosclerotic plaques in a subject, comprising administering to the subject a therapeutically effective amount of an osteopontin derived chemotactic peptide, wherein the peptide is not full-length osteopontin, such that formation of atherosclerotic plaques is prevented.

27-28. (canceled)

29. (withdrawn-currently amended) A method of inducing *in vivo* chemotaxis of a cell, comprising administering to a subject an osteopontin derived chemotactic peptide, wherein the peptide is not full-length osteopontin, for a time and under conditions effective to induce chemotaxis, wherein the cell bears receptors that recognize the peptide.

30. (withdrawn) The method of claim 22, wherein the cell is a mammalian cell.

31. (withdrawn) The method of claim 29, wherein the cell is selected from the group consisting of a smooth muscle cell, a macrophage, an endothelial cell, and a vascular cell.

32-33. (canceled)

34. (withdrawn) The method of claim 22, wherein the cell is selected from the group consisting of a smooth muscle cell, a macrophage, an endothelial cell, and a vascular cell.